Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract
- 1Department of Clinical Sciences, Ersta Hospital and Karolinska Institutet, Danderyd Hospital,Stockholm, Sweden
- 2Karolinska Institutet, Hematology Center, Karolinska University Hospital, Stockholm, Sweden
- 3Department of Clinical Sciences, Division of Internal Medicine, Karolinska Institutet, Stockholm, Sweden
- Correspondence to Dr Izabella Janczewska,
The prognosis in amyloid light chain (AL)-amyloidosis and multiorgan involvement is poor, with a high-treatment-related mortality after high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Some patients, however, might benefit from the therapy. We report a case of cardiac AL-amyloidosis with multiorgan involvement where the progressive cardiomyopathy was halted after successful treatment with HDM/SCT in 2001. The patient is in an excellent cardiac condition with a good quality of life, receiving treatment with angiotensinogen receptor blockers and a flexible diuretics regimen at follow-up after 10 years.
Competing interests None.
Patient consent Not obtained.